Skip to main content

Advertisement

SpringerLink
Log in

Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to evaluate the potential role of F-18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in assessing the chemotherapy response of osteosarcoma when compared with histologically assessed tumor necrosis.

Methods

Fifteen patients were examined with whole-body FDG-PET prior to and following neoadjuvant therapy. The maximum standard uptake value (SUVmax) of tumor and tumor to background ratio (TBR) prior to and following chemotherapy was used for semiquantitative PET imaging analysis. The SUVmax of prechemotherapy and post-chemotherapy was recorded as SUV1 and SUV2. TBR1 and TBR2 represented prechemotherapy and post-chemotherapy TBR. TBR was calculated by drawing an identical region of interest over the tumor and the contralateral normal limb or pelvis. Tumor necrosis was classified according to Salzer-Kuntschik’s criteria.

Results

Eight patients with more than 90% tumor necrosis were classified as showing good responses and seven patients with less than 90% tumor necrosis as showing poor responses. SUV2/SUV1, TBR2/TBR1, and TBR2 were significantly correlated with the tumor necrosis degree (P < 0.01, P < 0.001, P < 0.001). TBR2/TBR1 were below 0.46 in all the patients with favorable responses, and higher than 0.49 in all the patients with unfavorable responses. However, it was difficult to distinguish good responses from poor responses by SUV2/SUV1.

Conclusions

FDG-PET is a promising tool to assess the chemotherapy response of osteosarcoma noninvasively. The TBR was better than SUVmax in evaluating the chemotherapy response in this study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Saeter G, Kloke O, Jelic S; ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of osteosarcoma. Ann Oncol 2005;16Suppl 1:i71–i72.

    Article  PubMed  Google Scholar 

  2. Bielack S, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776–790.

    Article  PubMed  Google Scholar 

  3. Eilber FC, Rosen G, Eckardt J, Forscher C, Nelson SD, Selch M, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001;19:3203–3209.

    PubMed  CAS  Google Scholar 

  4. Bruzzi JF, Truong M, Zinner R, Erasmus JJ, Sabloff B, Munden R. Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy. J Thorac Oncol 2006;1:425–429.

    Article  PubMed  Google Scholar 

  5. Schwarz JD, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG-PET. J Nucl Med 2005;46:1144–1150.

    Google Scholar 

  6. Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514–1523.

    Article  PubMed  CAS  Google Scholar 

  7. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 2004;31:5–12.

    Article  PubMed  CAS  Google Scholar 

  8. Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006;243:472–478.

    Article  PubMed  Google Scholar 

  9. Feldman F, Heertum RV, Saxena C, Parisien M. 18FDG-PET applications for cartilage neoplasms. Skeletal Radiol 2005;34:367–374.

    Article  PubMed  Google Scholar 

  10. Györke T, Zajic T, Lange A, Schafer O, Moser E, Mako E, et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun 2006;27:17–24.

    Article  PubMed  Google Scholar 

  11. Kneisl JS, Patt JC, Johnson JC, Zuger JH. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas? Clin Orthop Relat Res 2006;450:101–104.

    Article  PubMed  Google Scholar 

  12. Tateishi U, Yamaguchi U, Seki U, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue [18F]fluorodeoxyglucose sarcomas: a prospective evaluation by positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:683–691.

    Article  PubMed  CAS  Google Scholar 

  13. Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging 2004;31:189–195.

    Article  PubMed  Google Scholar 

  14. Zhang H, Yoshikawa K, Tamura K, Tomemori T, Sagou K, Tian M, et al. [(11)C] methionine positron emission tomography and survival in patients with bone and soft tissue sarcomas treated by carbon ion radiotherapy. Clin Cancer Res 2004;10:1764–1772.

    Article  PubMed  CAS  Google Scholar 

  15. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980;153:106–120.

    PubMed  Google Scholar 

  16. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80. J Cancer Res Clin Oncol 1983;106Suppl:21–24.

    Article  PubMed  Google Scholar 

  17. Cullen JW, Jamroz BA, Stevens SL, Madsen W, Hinshaw I, Wilkins RM, et al. The value of serial arteriography in osteosarcoma: delivery of chemotherapy, determination of therapy duration, and prediction of necrosis. J Vasc Interv Radiol 2005;16:1107–1119.

    PubMed  Google Scholar 

  18. Kunisada T, Ozaki T, Kawai A, Sugihara S, Taguchi K, Inoue H. Imaging assessment of the responses of osteosarcoma patients to preoperative chemotherapy:angiography compared with thallium-201 scintigraphy. Cancer 1999;86:949–956.

    Article  PubMed  CAS  Google Scholar 

  19. Dyke JP, Panicek DM, Healey JH, Meyers PA, Huvos AG, Schwartz LH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during Induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 2003;228:271–278.

    Article  PubMed  Google Scholar 

  20. Jones DN, McCowage GB, Sostman HD, Brizel DM, Layfield L, Charles HC, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 1996;37:1438–1444.

    PubMed  CAS  Google Scholar 

  21. Abella E, Dicarli M, Ravindranath Y, Kottamasu S, Muzik O, Decamilo D, et al. Positron emission tomography [PET] scanning with 18-fluorodeoxyglcose[FDG] correlates with histological response in children with osteosarcoma [OS] and Ewing’s sarcoma [ES]. Proc Annu Meet Am Soc Clin Oncol 1996;15:1457.

    Google Scholar 

  22. Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999;40:1637–1643.

    PubMed  CAS  Google Scholar 

  23. Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000;25:874–881.

    Article  PubMed  CAS  Google Scholar 

  24. Nair N, Ali A, Green AA, Lamonica G, Alibazoglu H, Alibazoglu B, et al. Response of osteosarcoma to chemotherapy. Evaluation with F-18 FDG-PET scans. Clin Positron Imaging 2000;3:79–83.

    Article  PubMed  Google Scholar 

  25. Hawkins DS, Rajendran JG, Conrad EU III, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography. Cancer 2002;94:3277–3284.

    Article  PubMed  CAS  Google Scholar 

  26. Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 2003;44:717–724.

    PubMed  Google Scholar 

  27. Hawkins DS, Schuteze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU III, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23:8828–8834.

    Article  PubMed  Google Scholar 

  28. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU III, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339–348.

    Article  PubMed  Google Scholar 

  29. Langen KJ, Braun U, Rota Kops E, Herzog H, Kuwert T, Nebeling B, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993;34:355–359.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88, Jiefang Road, Hangzhou, Zhejiang, 310009, China

    Zhaoming Ye, Jiangjun Zhu, Disheng Yang, Weixu Li & Nong Lin

  2. Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

    Mei Tian, Hong Zhang, Hongwei Zhan & Chunlei Zhao

  3. Zhejiang University Medical PET Center, Hangzhou, China

    Mei Tian, Hong Zhang, Hongwei Zhan & Chunlei Zhao

  4. The Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou, China

    Mei Tian, Hong Zhang, Hongwei Zhan & Chunlei Zhao

Authors
  1. Zhaoming Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiangjun Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mei Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongwei Zhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chunlei Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Disheng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Weixu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nong Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhaoming Ye.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ye, Z., Zhu, J., Tian, M. et al. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET. Ann Nucl Med 22, 475–480 (2008). https://doi.org/10.1007/s12149-008-0147-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-008-0147-y

Keywords

Search

Navigation